Mayotte

Reimbursed Care Access

Mayotte follows French national law and regulatory practice: classical/plant-derived psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) are treated as stupéfiants with no authorised therapeutic use outside regulated clinical research. Ketamine is an authorised medical anaesthetic/analgesic and is used off‑label in psychiatry in hospital settings; esketamine (Spravato) has specific regulatory assessments in France and has not been accepted for broad public reimbursement by the French HAS. Clinical research on psychedelic compounds is possible in Mayotte under the French/European clinical‑trial framework (ANSM/CTIS/ethics committees).